Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2022) 81 EP1206 | DOI: 10.1530/endoabs.81.EP1206

ECE2022 Eposter Presentations Late Breaking (59 abstracts)

The impact of gh treatment in turner syndrome

Anamaria Hrisca1, Teodora Dumitru2, Diana Andrei2, Alexandru Florescu1, 2, Letitia Leustean1, 2, Cristina Rusu4, 5, Cristina Preda1, 2 & Maria Christina Ungureanu1, 2


1University of Medicine and Pharmacy ‘Grigore T. Popa‘, Endocrinology, Iasi, Romania; 2‘St. Spiridon‘ Clinical and Emergency Hospital, Endocrinology, Iasi, Romania; 4University of Medicine and Pharmacy ‘Grigore T. Popa‘, Clinical Genetics, Iasi, Romania; 5‘St Mary‘ Emergency Children Hospital, Clinical Genetics, Iasi, Romania


Introduction: The treatment with growth hormone (GH) plays an essential role in the Turner syndrome (TS) management. This study evaluated its efficacy in improving adult height (AH) and metabolic parameters.

Material and methods: We retrospectively analysed auxological, biochemical, genetic and pharmacological parameters of 56 girls with confirmed TS. They were categorised according to their karyotype as X monosomy (62%), isochromosome (17%), X mosaicism (11%) and ring X chromosome (10%). They were aged 10.85 ±4.008 years at the initiation of the treatment, and the average GH treatment duration was 4.36 ± 2.82 years with a dose of 0.035-0.05 mg/kg/day.

Results: The GH treatment significantly increased height between the first and the last visit (123.36 ± 17.78 cm vs 150.45 ± 7.37 cm). There was a significant correlation between the initial age and the final height. IGF1 serum level was low in 15 patients before treatment and raised to normal values during treatment. Nine patients were overweight and the BMI did not significantly change during treatment. The total cholesterol and triglycerides decreased after the initiation of the treatment (from 173.87 ± 27.59 mg/dl to 155.69 ± 31.06 mg/dl and 79.25 ± 44.07 to 75.6 ± 34.61). Fasting plasma glucose raised from 87.53 ± 10.57 to 93.85 ± 9.35 mg/dl, with only a few isolated cases of hyperglycemia (6 patients). There was no significant change in terms of hepatic enzymes during treatment. Vitamin D deficiency was identified in 17 patients (16.13 ± 4.3 ng/ml). Eleven girls (19.6%) presented autoimmune thyroiditis, ten girls - cardiac anomalies, 2 - renal malformation and 4 - celiac disease. The treatment had no negative impact on cardiac function.

Conclusion: Our study strengthens the literature findings that GH treatment at an early age effectively improves the final height. GH therapy has additional positive effects on serum lipids, without adverse effects on carbohydrate metabolism, hepatic function or cardiac modifications, confirming treatment safety in TS girls.

Volume 81

European Congress of Endocrinology 2022

Milan, Italy
21 May 2022 - 24 May 2022

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.

My recently viewed abstracts